SLCO1B1 T521C基因多态性对他汀类药物药代动力学影响的Meta分析

张刚; 陈磊; 李灵敏; 叶钧; 陈文生

doi:10.16016/j.1000-5404.201612183

您当前的位置：

首页 >

文章列表页 >

SLCO1B1 T521C基因多态性对他汀类药物药代动力学影响的Meta分析

公共卫生学与预防医学 | 更新时间：2026-02-09

- SLCO1B1 T521C基因多态性对他汀类药物药代动力学影响的Meta分析
- Influence of SLCO1B1 gene T521C polymorphism on pharmacokinetics of HMG-CoA reductase inhibitors: a meta-analysis
- 第三军医大学学报 2017年39卷第10期页码：1036-1043
- 作者机构：
  
  400038 重庆，第三军医大学西南医院全军消化病研究所
- 作者简介：
  
  [陈文生，E-mail：wenshengchen@hotmail.comChen Wensheng, E-mail: wenshengchen@hotmail.com
- 基金信息：
  
  国家自然科学基金面上项目(81470850)
- DOI：10.16016/j.1000-5404.201612183
  中图分类号： R394.6;R969.1;R972.6
- 收稿：2016-12-21，
  
  修回：2017-02-21，
  
  纸质出版：2017-05-30
- 稿件说明：
移动端阅览
张刚, 陈磊, 李灵敏, 等. SLCO1B1 T521C基因多态性对他汀类药物药代动力学影响的Meta分析[J]. 第三军医大学学报, 2017,39(10):1036-1043.

Gang Zhang, Lei Chen, Lingmin Li, et al. Influence of SLCO1B1 gene T521C polymorphism on pharmacokinetics of HMG-CoA reductase inhibitors: a meta-analysis[J]. Journal of Third Military Medical University, 2017, 39(10): 1036-1043.
张刚, 陈磊, 李灵敏, 等. SLCO1B1 T521C基因多态性对他汀类药物药代动力学影响的Meta分析[J]. 第三军医大学学报, 2017,39(10):1036-1043. DOI： 10.16016/j.1000-5404.201612183.

Gang Zhang, Lei Chen, Lingmin Li, et al. Influence of SLCO1B1 gene T521C polymorphism on pharmacokinetics of HMG-CoA reductase inhibitors: a meta-analysis[J]. Journal of Third Military Medical University, 2017, 39(10): 1036-1043. DOI： 10.16016/j.1000-5404.201612183.

摘要

目的

采用Meta分析评价SLCO1B1 T521C基因多态性与他汀类药物药代动力学参数的关系。

方法

计算机检索Pubmed、EMBASE、Cochrane Library、中国生物医学文献数据库、中国期刊全文数据库、万方、维普数据库，收集有关SLCO1B1 T521C基因多态性和他汀类药物药代动力学关系的研究。提取AUC

0~6 h

、AUC

0~12 h

、AUC

0~24 h

、AUC

0-inf

、C

max

和CL/F等药代动力学参数。用标准均数差(

SMD

)和95%

比较野生型(TT)基因型和突变基因型(TC、CC、TC+CC)。亚组分析根据种族人群、他汀类药物的类型进行。用敏感性分析对各项研究进行异质性检验。用RevMan 5.3软件对符合纳入标准的研究进行Meta分析。

结果

共纳入25篇文献903例病例，Meta分析结果显示：全部研究的AUC

0-inf

标准均数差TT-TC为0.51(95%

: 0.29~0.72)，TT-CC为1.80(95%

: 1.31~2.29)，TT-(TC+CC)为0.78(95%

: 0.57~0.99)；突变基因型的AUC

0-inf

的标准均数差较高。在白种人和亚洲人的亚组分析得出同样的结果。全部研究的C

max

标准均数差TT-TC为0.48(95%

: 0.18~0.77)，TT-CC为1.24(95%

: 0.77~1.70)，TT-(TC+CC)为0.65(95%

: 0.43~0.87)；突变基因型的C

max

的标准均数差也较高。在白种人和亚洲人的亚组分析也得出同样的结果。全部研究的CL/F标准均数差TT-TC为-1.01(95%

: -1.91~-0.11)，TT-CC为-1.51(95%

: -2.08~-0.94)，TT-(

TC+CC)为-1.07(95%

: -1.55~-0.59)，突变基因型的CL/F的标准均数差较低。

结论

SLCO1B1 T521C等位基因可能对他汀类药物药代动力学起着重要影响。

Abstract

Objective

To evaluate the influence of SLCO1B1 gene T521C polymorphisms on the pharmacokinetics of statins.

Methods

We searched PubMed

EMBASE

Cochrane Library

CBM

CNKI

WANFANG

and VIP databases for studies that investigated the influence of SLCO1B1 gene T521C polymorphisms on pharmacokinetics of statins. The pharmacokinetic parameters including the areas under the concentration-time curves following statin administration (AUC

0~6 h

AUC

0~12 h

AUC

0~24 h

and AUC

0-inf

)

the maximum plasma drug concentration (C

max

) and oral clearance (CL/F) were extracted from the included studies. The standardized mean differences (SMD) and 95% confidence intervals (95%

) of the pharmacokinetic parameters were calculated for comparison between subjects with TT genotype and mutant genotypes. Subgroup analyses were carried out for different ethnic populations and statin types

and sensitivity analysis was used to test the heterogeneity of the studies.

Results

Twenty-five studies were eligible for analysis

including 23 published in English and 2 in Chinese involving a total of 903 subjects. Meta-analysis of the studies showed that the SWD of the AUC

0-inf

of the subjects with TT-TC

TT-CC

and TT-(TC+CC) genotypes was 0.51 (95%

: 0.29~0.72)

1.80 (95%

: 1.31~2.29) and 0.78 (95%

: 0.57~ 0.99)

respectively

suggesting a higher SWD of AUC

0-inf

in mutant genotypes than in the wild-type genotype. The same result was obtained in subgroup analysis of Caucasian and Asian populations. The SWD of C

max

in subjects with TT-TC

TT-CC

and TT-(TC+CC) genotypes was 0.48

(95%

: 0.18~0.77)

1.24 (95%

: 0.77~1.70) and 0.65 (95%

: 0.43~0.87)

respectively

also higher in the mutant genotypes; subgroup analysis of Caucasian and Asian populations also yielded the same result. The SWD of CL/F in the subjects with the 3 genotypes was -1.01 (95%

: -1.91~-0.11)

-1.51 (95%

: -2.08~-0.94) and -1.07 (95%

: -1.55~-0.59)

respectively

lower in the mutant genotypes than in the wild-type genotype.

Conclusion

SLCO1B1 gene T521C allele may have an important effect on the pharmacokinetics of statins.

关键词

Keywords

references

Ballantyne C M, Corsini A, Davidson M H, et al. Risk for myopathy with statin therapy in high-risk patients[J]. Arch Intern Med, 2003, 163(5): 553-564.

Romaine S P, Bailey K M, Hall A S, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy[J]. Pharmacogenomics J, 2010. 10(1): 1-11.DOI:10.1038/tpj.2009.54.

Stroup D F, Berlin J A, Morton S C et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000. 283(15): 2008-2012.

Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression[J]. Br J Clin Pharmacol, 2005, 60(2): 159-171. DOI: 10.1111/j.1365-2125.2005.02392.x.

Hozo S P, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample[J]. BMC Med Res Methodol, 2005, 5: 13. DOI: 10.1186/1471-2288-5-13.

Field A P. Meta-analysis of correlation coefficients: a Monte Carlo comparison of fixed-and random-effects methods[J]. Psychol Methods, 2001, 6(2): 161-180. DOI: 10.1037//1082-989x.6.2.161.

Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics[J]. Clin Pharmacol Ther, 2004, 75(5): 415-421. DOI: 10.1016/j.clpt.2003.12.016.

Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)[J]. Pharmacogenetics, 2004, 14(7): 429-440.

Chung J Y, Cho J Y, Yu K S, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers[J]. Clin Pharmacol Ther, 2005, 78(4): 342-350. DOI: 10.1016/j.clpt.2005.07.003.

Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment[J]. Clin Pharmacol Ther, 2005, 78(4): 330-341. DOI:10.1016/j.clpt.2005.06.013.

Hedman M, Antikainen M, Holmberg C, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes[J]. Br J Clin Pharmacol, 2006, 61(6): 706-715. DOI: 10.1111/j.1365-2125.2006.02643.x.

Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril[J]. Clin Pharmacol Ther, 2006, 79(5): 427-439. DOI: 10.1016/j.clpt.2006.01.011.

Niemi M, Pasanen M K, Neuvonen P J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin[J]. Clin Pharmacol Ther, 2006, 80(4): 356-366. DOI: 10.1016/j.clpt.2006.06.010.

Pasanen M K, Neuvonen M, Neuvonen P J, et al. SLCO/B1 polymorphism markedly affects the phrmacokinetics of simvatatin aid. Phormacogenet Genomics[J], 2016, 16(12): 873-879. DOI: 10.1097/01.fpc.0000230416.82349.90.

Ho R H, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants[J]. Pharmacogenet Genomics, 2007, 17(8): 647-656. DOI: 10.1097/FPC.0b013e3280 ef698f.

Pasanen M K, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin[J]. Clin Pharmacol Ther, 2007, 82(6): 726-733. DOI: 10.1038/sj.clpt.6100220.

温爱萍, 徐小薇, 严晓伟.有机阴离子转运多肽1B1遗传多态性对普伐他汀药动学的影响[J].中国药学杂志, 2008, 43(22): 1735-1739. DOI: 10.3321/j.issn:1001-2494.2008.22.013.

Wen A P, Xu X W, Yan X W. Effects of genetic polymorphism of OATP1B1 on pharmacokinetics of pravastatin[J]. Chinese Pharmaceutical Journal, 2008, 43(22): 1735-1739. DOI: 10.3321/j.issn:1001-2494.2008.22.013.

Choi J H, Lee M G, Cho J Y, et al. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans[J]. Clin Pharmacol Ther, 2008, 83(2): 251-257. DOI: 10.1038/sj.clpt.6100267.

Deng J W, Song I S, Shin H J, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15[J]. Pharmacogenet Genomics, 2008, 18(5): 424-433. DOI: 10.1097/FPC.0b013 e3282fb02a3.

Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1[J]. Clin Pharmacol Ther, 2008, 83(3): 471-476. DOI: 10.1038/sj.clpt.6100318.

Kalliokoski A, Backman J T, Kurkinen K J, et al. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism[J]. Clin Pharmacol Ther, 2008, 84(4): 488-496. DOI: 10.1038/clpt.2008.74.

Suwannakul S, Ieiri I, Kimura M, et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism[J]. J Hum Genet, 2008, 53(10): 899-904. DOI: 10.1007/s10038-008-0324-9.

He Y J, Zhang W, Chen Y, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism[J]. Clin Chim Acta, 2009, 405(1-2): 49-52. DOI: 10.1016/j.cca.2009.04.003.

Lee Y J, Lee M G, Lim L A, et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects[J]. Int J Clin Pharmacol Ther, 2010, 48(1): 36-45. DOI: 10.5414/cpp48036.

随双明, 温金华, 李新华, 等. OATP1B1基因位点521T→C的突变对瑞舒伐他汀在中国健康人体内药代动力学特征的影响[J].药学学报, 2011, 46(6): 695-700.

Sui S M, Wen J H, Li X H, et al. Effect of OATP1B1 521T →C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers[J]. Acta pharmaceutica Sinica, 2011, 46(6): 695-700.

Choi C I, Lee Y J, Lee H I, et al. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin[J]. Xenobiotica, 2012, 42(5): 496-501. DOI: 10.3109/0049 8254.2011.632030.

Zhou Q, Ruan Z R, Yuan H, et al. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers[J]. Arzneimittelforschung, 2012. 62(11): 519-524. DOI: 10.1055/s-0032-1323696.

Zhou Q, Ruan Z R, Jiang B, et al. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms[J]. Pharmazie, 2013, 68(2): 124-128.

Zhu J, Song M, Tan H Y, et al. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males[J]. Pak J Pharm Sci, 2013, 26(3): 577-584. DOI:10.1097/01.hjh.0000408034.54484.7d.

Tornio A, Vakkilainen J, Neuvonen M, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid[J]. Pharmacogenet Genomics, 2015, 25(8): 382-387. DOI: 10.1097/FPC.0000000000000148.

Liu M,Wu X J, Zhao G L, et al. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers[J]. J Cardiovasc Pharmacol, 2016, 68(5): 383-390. DOI: 10.1097/FJC.0000000000000426.

van de Steeg E, Wagenaar E, van der Kruijssen C M, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs[J]. J Clin Invest, 2010, 120(8): 2942-2952. DOI:10.1172/JCI42168.

Rodrigues AC. Efflux and uptake transporters as determinants of statin response[J]. Expert Opin Drug Metab Toxicol, 2010, 6(5): 621-632. DOI: 10.1517/1742525 1003713519.

Morimoto K, Oishi T, Ueda S, et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy[J]. Drug Metab Pharmacokinet, 2004, 19(6): 453-455. DOI: 10.2133/dmpk.19.453.

Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005, 15(7): 513-522. DOI: 10.1097/01.fpc.0000170913.73780.5f.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

IL-1α-889基因多态性与慢性牙周炎易感性的Meta分析

中国人群ApoE基因多态性与2型糖尿病相关性的Meta分析

基于系统评价和Meta分析的糖尿病足溃疡患者截肢风险预测模型的开发和验证

注射用右旋雷贝拉唑钠在健康人体内的药代动力学和药效学研究

新型冠状病毒肺炎患者转氨酶水平的Meta分析